Loading...
Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories
Зохиогч
Devin Razavi‐Shearer
H. Child
K. Razavi-Shearer
Alexis S. Voeller
Homie A. Razavi
Marı́a Buti
Frank Tacke
Norah A. Terrault
Stefan Zeuzem
Zaigham Abbas
Alessio Aghemo
Ulus Salih Akarca
Nasser Al Masri
A. Alalwan
Marianne Alanko Blomé
Anna Jerkeman
Soo Aleman
Habiba Kamal
Abdullah Alghamdi
M. Alghamdi
Saad Ali Alghamdi
Waleed Al-hamoudi
E. Ali
Abdulrahman Abdullah Aljumah
Ibrahim Altraif
J. Amarsanaa
Tarik Asselah
Adriana Babameto
Ziv Ben‐Ari
Thomas Berg
Mia J. Biondi
Wornei Silva Miranda Braga
Carlos Eduardo Brandão‐Mello
Robert S. Brown
Maurizia Rossana Brunetto
Joaquín Cabezas
Mariana Ferreira Cardoso
A. Martins
Henry Lik‐Yuen Chan
Hugo Cheinquer
C.-J. Chen
Hwai‐I Yang
Pei‐Jer Chen
Cheng‐Hung Chien
Wan‐Long Chuang
L. Cisneros Garza
B. Coco
Carla S. Coffin
Nicola Coppola
Markus Cornberg
Antonio Craxı̀
Javier Crespo
Liri Çuko
Victor de Lédinghen
Ann‐Sofi Duberg
Ohad Etzion
Maria Lúcia Gomes Ferraz
Paulo Roberto Abrão Ferreira
Xavier Forns
Graham R. Foster
James Fung
Giovanni Battista Gaeta
Javier García‐Samaniego
J Genov
Liliana Simona Gheorghe
P. Gholam
Robert Gareth Gish
Jeffrey S. Glenn
Saeed Sadiq Hamid
Julian Hercun
Yao‐Chun Hsu
Chih-Chien Hu
Jee‐Fu Huang
Ramazan Idılman
Wasim Jafri
Naveed Zafar Janjua
Deian Jelev
Jidong Jia
Martin Kåberg
Kelly Kaita
Jia‐Horng Kao
Aamir Ghafoor Khan
D. Y. Kim
Loreta Anesti Kondili
Martin Lagging
Pietro Lampertico
Pablo Lázaro
Jeffrey Victor Lazarus
M.-H. Lee
Hwai‐I Yang
Young‐Suk Lim
Cirley Lobato
Guilherme Macedo
Rui Tato Marinho
Paul Marotta
Maria Cássia Mendes-Corrêa
Nahúm Méndez‐Sánchez
M.-C. Navas
Qing Xiu Ning
Он
2023 оны арван нэгдүгээр сарын 27
Төрөл
journal article
Хэвлэгч
Elsevier BV
Journal
Journal of Hepatology
Volume
80
Issue
2
Start Page
232
End Page
242
ISSN
0168-8278
1600-0641
Хураангуй
BACKGROUND & AIMS: Hepatitis delta virus (HDV) is a satellite RNA virus that requires the hepatitis B virus (HBV) for assembly and propagation. Individuals infected with HDV progress to advanced liver disease faster than HBV-monoinfected individuals. Recent studies have estimated the global prevalence of anti-HDV antibodies among the HBV-infected population to be 5-15%. This study aimed to better understand HDV prevalence at the population level in 25 countries/territories. METHODS: We conducted a literature review to determine the prevalence of anti-HDV and HDV RNA in hepatitis B surface antigen (HBsAg)-positive individuals in 25 countries/territories. Virtual meetings were held with experts from each setting to discuss the findings and collect unpublished data. Data were weighted for patient segments and regional heterogeneity to estimate the prevalence in the HBV-infected population. The findings were then combined with The Polaris Observatory HBV data to estimate the anti-HDV and HDV RNA prevalence in each country/territory at the population level. RESULTS: After adjusting for geographical distribution, disease stage and special populations, the anti-HDV prevalence among the HBsAg+ population changed from the literature estimate in 19 countries. The highest anti-HDV prevalence was 60.1% in Mongolia. Once adjusted for the size of the HBsAg+ population and HDV RNA positivity rate, China had the highest absolute number of HDV RNA+ cases. CONCLUSIONS: We found substantially lower HDV prevalence than previously reported, as prior meta-analyses primarily focused on studies conducted in groups/regions that have a higher probability of HBV infection: tertiary care centers, specific risk groups or geographical regions. There is large uncertainty in HDV prevalence estimates. The implementation of reflex testing would improve estimates, while also allowing earlier linkage to care for HDV RNA+ individuals. The logistical and economic burden of reflex testing on the health system would be limited, as only HBsAg+ cases would be screened. IMPACT AND IMPLICATIONS: There is a great deal of uncertainty surrounding the prevalence of hepatitis delta virus among people living with hepatitis B virus at the population level. In this study, we aimed to better understand the burden in 25 countries and territories, to refine techniques that can be used in future analyses. We found a lower prevalence in the majority of places studied than had been previously reported. These data can help inform policy makers on the need to screen people living with hepatitis B virus to find those coinfected with hepatitis delta virus and at high risk of progression, while also highlighting the pitfalls that other researchers have often fallen into.